PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Neurocrine Biosciences, Inc. for the ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Neurocrine Biosciences’ US FDA approved crinecerfont is available for children and adults to treat classic congenital adrenal hyperplasia: San Diego Tuesday, December 24, 2024, ...

Neurocrine Biosciences' CEO, Kyle W. Gano, Ph.D., emphasized the significance of Crenessity, stating that it provides a ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and ...

研究为理解创伤后应激障碍（PTSD）、自闭症和精神分裂症等疾病提供了新的见解。识别调节共鸣反应的特定大脑机制可以帮助临床研究开发新的靶向疗法，也能够帮助改善在各种精神状况中观察到的异常情绪反应。

In this edition of “Rising High,” The Fly conducted an exclusive interview with Hans Eriksson, Chief Medical Officer of HMNC Brain Health, a ...

The comorbidity burden of alopecia areata includes an increased risk for autoimmune and psychiatric conditions, like ...

The interaction between homeostasis-disturbing stressors and stressor-activated adaptive responses of the organism can have three potential outcomes. First, the match may be perfect and the ...

Crenessity a potent and selective oral corticotropin-releasing factor type 1 receptor antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone ...

The California Technology Assessment Forum (CTAF) has been requested to review the scientific evidence for the use of sleeve gastrectomy (SG) also known as vertical sleeve gastrectomy (VSG) or ...